Search the database for deliberate release of GM medicinal products
Displaying 1 - 7 of 7
|EU record number
|Company / Sponsor
|Dossier withdrawn by the notifier
|V181 is a live attenuated dengue quadrivalent vaccine rDENVΔ30 where the four viral components of V181 (one for each serotype) present a deletion of 30 nucleotides in the 3’ non‐coding region (Δ30)
|Only notified under the "contained use" procedure. Dossier submitted on 07/04/2017.
|Phase 1 clinical trial evaluation of two genetically modified vaccines against poliovirus
|Genetic modifications of the nOPV2 vaccine candidates aimed at stabilizing the genetic sequence against reversion compared to the Sabin-2 strain, nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3), nOPV2 candidate 2 (S2/S15domV/CpG40)
|Only notified under the "contained use" procedure. Dossier submitted on 07/04/2014.
|A single-center, open-label Phase 1 study to assess safety and medical endoscopic sampling methodology and to characterize the pharmacokinetics of oral doses of AG014 in Healthy Subjects
|gene expressing certolizumab
|Only notified under the "contained use" procedure. Dossier submitted on 08/05/2012.
|A single-center, open-label Phase 1 study to assess the effect of food/beverage and to characterisze the pharmacokinetics of single and multiple oral doses of AG013 in Healthy Subjects
|Human Trefoil Factor 1
|Clinical Study BNIT-PRV-301 - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
|Human gene coding for the prostate-specific antigen (PSA) and genes encoding 3 human immunological costimulatory molecules
|Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis
|Gene coding for the human interleukin-10 (hIL-10)
|Only notified under the "contained use" procedure. Dossier submitted on 09/06/1998.
|A phase II, multi-center, open label, randomized study to evaluate biodistribution and transmission, effectiveness and safety of two treatment regimens of Ad5CMV-p53 administered by intra-tumoral injections in 40 evaluable patients with advanced squamous